Cantor Fitzgerald started coverage on shares of Aardvark Therapeutics (NASDAQ:AARD – Free Report) in a research note issued to investors on Monday morning, Marketbeat reports. The brokerage issued an overweight rating and a $50.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Aardvark Therapeutics’ FY2024 earnings at ($3.89) EPS and FY2025 earnings at ($2.49) EPS.
Aardvark Therapeutics Price Performance
NASDAQ AARD opened at $10.14 on Monday. Aardvark Therapeutics has a one year low of $9.21 and a one year high of $19.58.
Insider Transactions at Aardvark Therapeutics
In related news, CEO Tien-Li Lee bought 16,542 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $264,672.00. Following the purchase, the chief executive officer now directly owns 1,496,175 shares of the company’s stock, valued at approximately $23,938,800. This trade represents a 1.12 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Nelson Sun bought 10,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average price of $16.00 per share, with a total value of $160,000.00. Following the completion of the purchase, the chief financial officer now directly owns 99,484 shares in the company, valued at $1,591,744. This represents a 11.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here.
About Aardvark Therapeutics
We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.
Featured Articles
- Five stocks we like better than Aardvark Therapeutics
- Best Stocks Under $5.00
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
